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Background: Treatment of hepatitis C virus (HCV) infection with interferon (IFn) and ribavirin 
(RBV) is associated with adverse events, which may affect the patient’s adherence to the treat-
ment regimen and the treatment efficacy. 
Objectives: The aim of this study was to assess the sustained viral response (SVR) and interde-
pendence between the haematological characteristics (leukocyte count, platelet count, and 
haemoglobin levels) in patients with chronic hepatitis C (CHC) infection during treatment 
with IFn and RBV.
Patients and Methods: We conducted a retrospective cohort study of 170 children with CHC 
infection who completed treatment with IFn-α and RBV. The children were divided into 2 
groups: the first group (group I, n = 119) underwent a 48-week course of treatment with re-
combinant IFn α-2b (Intron A) at a dosage of 3 MU 3 times a week subcutaneously and RBV at 
a dosage of 15 mg/kg per day orally, and the second group (group II, n = 51) was administered 
pegylated IFn (peg-IFn)-α-2b (pegIntron) at a dosage of 1.5 µg/kg per week subcutaneously and 
RBV at a dosage of 15 mg/kg per day orally for 48 weeks. The dose of IFn was not adjusted but 
that of ribavirin was in 2 children from group II. Hematological growth factors and erythro-
poietin were not used. SVR was defined as undetectable serum HCV RnA 24 weeks after the 
end of treatment (study week 72). Serum HCV RnA was determined by performing polymer-
ase chain reaction, and the HCV genotypes and hematological parameters were evaluated. 
Serum HCV RnA levels were analysed by descriptive statistics. Means and standard deviations 
were calculated for values collected at the baseline, on the 12th and 48th weeks during treat-
ment, and after 24 weeks of untreated follow-up (study week 72).
Results: eighty-six (50%) of the 170 patients who underwent treatment achieved SVR: 62 (51%) 
out of 119 children from group I and 24 (47%) out of 51 from group II. The mean serum hemo-
globin levels and leukocyte and platelet counts at week 12 were significantly lower than the 
baseline values in both responders and non-responders from both the groups (P < 0.05). In 
the responders in group I, the mean levels of serum hemoglobin after 24 weeks of treatment 
and at the end of therapy were significantly lower than the mean levels at baseline. In the 
group treated with peg-IFn-α-2b and RBV (group II), the mean serum hemoglobin levels at 
week 12 was lower in the responders than in the non-responders (P < 0.05). The decrease in 
the hemoglobin levels was associated with viral response. In both the responders and non-
responders from both the groups, leukocyte counts decreased during treatment, and after 
12 weeks, they were more significantly lower than the baseline value. The decrease was more 
marked in children treated with peg-IFn-α-2b + RBV (P < 0.05). After 12 weeks of treatment, the 
platelet count was low in children from group II who had achieved SVR. 
Conclusions: A mild decrease in hemoglobin levels and leukocyte and platelet counts during 
treatment with IFn and RBV in children with CHC infection may be factors responsible for 
SVR induction. 
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 Implication for health policy/practice/research/medical education:
The aim of the study was to assess the dependences between the kinetics of haematological exponents (leukocytes count, platelets count, 
haemoglobin level) during CHC treatment with interferon and ribavirin and viral response.our data has demonstrated that mild decrease of 
hemoglobin levels, leukocytes and platelets counts during treatment with IFn and ribavirin of chronic hepatitis C in children may constitute 
the factors of achieving sustained virologic response. Thus,  close monitoring of blood counts during treatment is necessary. This article is 
important for hepatologists and pediatric medicine doctors, who treat patients with chronic hepatitis C.
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1. Background
Hepatitis C virus (HCV) infection is the leading cause 
of chronic liver disease and cirrhosis, and it is the most 
common underlying diagnosis in patients who undergo 
liver transplant. Children form only a small proportion 
of the HCV-infected population, but there are a signifi-
cant number of children with chronic HCV (CHC) infec-
tion (1). In children, HCV infection is considered to be a 
mild asymptomatic disease that has a limited histologi-
cal  spectrum  and  in  which  the  serum  alanine  amino-
transferase (ALT) levels are mostly normal. Clinical symp-
toms  of  HCV  infection  are  observed  in  approximately 
20% of the infected children, with hepatomegaly being 
the most frequently observed sign (2). Because of the pos-
sibility of serious late clinical consequences such as liver 
cirrhosis  and  hepatocellular  carcinoma,  children  with 
CHC should be administered antiviral treatment (3). The 
main goal of therapy for HCV infection is to achieve a 
sustained virological response (SVR), which is practically 
equivalent to the eradication of HCV infection and cure 
of the underlying HCV-induced liver disease. Currently, 
the standard treatment for adults with HCV infection is 
a combination therapy with pegylated interferon (peg-
IFn)-α-2b  and  ribavirin  (RBV).  The  application  of  this 
therapy in children was approved by the Food and Drug 
Administration in December 2008 and by the European 
Agency for the evaluation of Medicinal products in no-
vember 2009. This therapy is very effective and secures 
a high quality of life for the patient, which is very impor-
tant, especially in the case of children (2, 4, 5). 
The efficacy of the combination therapy with peg-IFn-
α-2b and RBV in children with HCV infection is compa-
rable to and even higher than that reported in adults. 
This possibly better viral response in children may be 
associated with shorter duration of HCV infection, lower 
frequency of liver fibrosis and iron overload, and lower 
rate of risky behavior (intravenous drug usage, alcohol 
consumption, etc.) and comorbidities (4-6). Treatment 
with peg-IFnα-2b and RBV is associated with several, and 
sometimes severe, adverse events, which may affect the 
treatment  efficacy  and  the  patient’s  adherence  to  the 
treatment regimen. Side effects of such a combination 
therapy mainly include fever, headache, fatigue, flu-like 
syndrome, and hematological disorders such as leucope-
nia, thrombocytopenia, and anemia. Depression, weight 
loss, thyroiditis, and other autoimmune diseases such as 
decrease in height growth, especially in children, have 
also been reported to be the side effects of the combina-
tion therapy (5, 7, 8). 
2. Objectives
The aim of this study was to assess the SVR and interde-
pendence between the hematological parameters (leu-
kocyte count, platelet count, hemoglobin levels) during 
the treatment of CHC infection with IFn and RBV.
3. Patients and Methods
We conducted a retrospective cohort study of 170 chil-
dren with CHC infection who completed treatment with 
recombinant IFn-α-2b, peg-IFn-α-2b, and RBV (Schering-
plough) from March 2000 to June 2006. The protocol 
was approved by the ethics committee of the Collegium 
Medicum of the nicolaus Copernicus University, Bydgo-
szcz, poland. Informed consent was obtained in writing 
from the legal guardian of each patient before the treat-
ment was initiated. Children who were considered eli-
gible for the treatment had CHC infection that had been 
diagnosed on the basis of the presence of HCV RnA in the 
serum and the histopathological changes in the liver. 
During the treatment, patients returned to the clinic at 
regular intervals, at which time their blood samples were 
collected for determining serum HCV RnA viral load and 
ALT activity. A complete blood count was performed dur-
ing each clinical visit. Baseline characteristics of the ex-
amined children have been listed in Table 1. 
All the children had to undergo liver biopsy and liver 
untrasonography as a prerequisite for enrollment and 
treatment. Liver biopsy specimens were scored accord-
ing  to  the  modified  Scheuer  scale  and  were  assigned 
a  grade  between  0  and  4  for  necroinflammation  and 
a stage between 0 and 4 for fibrosis (9). The severity of 
liver disease did not exceed grade 2 and stage 2 in any 
child. patients with chronic liver disease other than CHC 
or those who were co-infected with hepatitis B virus or 
human immunodeficiency virus were not considered eli-
gible. The children were divided into 2 groups—the first 
group (n = 119) of children were administered a 48-week 
course  of  recombinant  IFn-α-2b (Intron A) subcutane-
ously at a dosage of 3 MU 3 times a week and RBV at a dos-
age of 15 mg/kg per day orally, and the second group (n 
= 51) of children were administered peg-IFn-α-2b (PegIn-
tron) at a dosage of 1.5 µg/kg per week subcutaneously 
and RBV 15 mg/kg per day orally for 48 weeks. The dose 
of IFn was not adjusted but that of RBV was in the case 970 Hematological Characteristics and SVR in Treatment of HCV Pawlowska M et al.
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of 2 children from group II. Hematological growth fac-
tors and erythropoietin were not used. SVR was defined 
as undetectable HCV RnA in the serum 24 weeks after the 
end of treatment.
Serum HCV-RnA viral load was determined at the base-
line, at the 12th and 48th weeks during treatment, and after 
24 weeks of untreated follow-up (study week 72) by per-
forming quantitative polymerase chain reaction (PCR) 
(CoBAS®  Ampliprep/CoBAS  TaqMan®  HCV  Test;  Roche 
Diagnostics Geneva, Switzerland), which had a detection 
limit of 43 IU/mL. The primary efficacy variable was the 
proportion of patients who attained SVR. The genotypes 
of HCV were identified by performing the InnoGeneT-
ICS Inno-LipA HCV II test. Hematological parameters (he-
moglobin levels, leukocyte counts, and platelet counts) 
were evaluated at baseline, at the 12th and 24th weeks, and 
at the end of the therapy by using Sysmex 4500. 
3.1. Statistical Analysis
Hemoglobin  levels,  leukocyte  counts,  and  platelet 
counts  were  analyzed  by  using  descriptive  statistics. 
Means and standard deviations were calculated for val-
ues recorded at baseline, at the 12th and 24th weeks, and at 
the end of the treatment. We used Student’s t test, Mann–
Whitney U test, and the chi-squared test for the statistical 
analyses. 
4. Results
SVR was achieved in 86 (50%) of the 170 treated chil-
dren: 62 (51%) of 119 children from group I and 24 (47%) 
of 51 from group II. In the baseline examination of both 
the groups of patients, no statistically significant differ-
ences  were  observed  in  the  serum  hemoglobin  levels, 
leukocyte  count,  and  platelet  count  between  the  chil-
dren who achieved SVR (responders) and those who did 
not (non-responders). In both the treatment groups, 
we observed significant and similar decrease in the he-
matological parameters that were analyzed during the 
therapy. The serum hemoglobin levels decreased during 
treatment in the responders and non-responders from 
both the groups (Figure 1 A and 1B). In group I, the mean 
serum hemoglobin levels after 24 weeks of the treatment 
and at the end of the therapy were significantly lower in 
children who achieved SVR, especially treatment-naïve 
children (P < 0.05) (Table 2). In group II, the mean se-
rum hemoglobin levels were significantly lower in the 
responders after 12 weeks of therapy. During the later 
course of the treatment, the differences were not statisti-
cally significant. In the responders and non-responders 
from both the groups, the leukocyte counts decreased 
during the treatment, and after the 12th week, they were 
significantly lower than the baseline measurement. The 
decrease  was  more  marked  in  children  treated  with 
peg-IFn-α-2b and RBV (pegIFn + RBV) (Figure 2A and 2B). 
The leukocyte counts after 12 weeks were significantly 
lower in children treated with peg-IFn-α-2b + RBV than in 
those treated with IFn and RBV (SVR, P < 0.05 and  non-
responders nR, P < 0.05) (Table 3).
The platelet counts during the therapy were within the 
normal range; they decreased during the treatment and 
were significantly lower after 12 weeks than at the base-
line in both the responders and non-responders from 
both the groups (P < 0.05) (Figure 3A and 3B). After 12 
weeks of treatment, the platelet count was lower in chil-
dren from group II who had achieved SVR (Table 4). 
5. Discussion
Hematological complications such as anemia, throm-
bocytopenia, and leucopenia are common and frequent 
side effects of combination therapy with interferon and 
RBV, but their intensity ranges from mild to moderate. 
Treated With IFN a α-2b + RBV a, 
Group I (n = 119)
Treated With Pegylated IFN -α-2b + RBV, 
Group II (n = 51)
Sex
Female
Male
Age, y, (mean)
41
78
1–18 (11.7)
15
36
8–18 (13.6)
HCV genotype, no. (%)
1
4
48/75 (64)
27/75 (36)
27/51 (53)
24/51 (47)
Baseline HCV RnA, IU/mL b, mean ± SD 3.58 ± 1.17 × 105 8.98 ± 6.19 × 105  b
ALT activity, U/L, mean ± SD 59.4 ± 24.0 46.1 ± 22.0
Liver biopsy, mean ± SD
Grading
Staging
1.11 ± 0.49
0.68 ± 0.49
0.92 ± 0.46
0.63 ± 0.53
Treatment-naïve, no. (%)  101 (85) 26 (51)
Retherapy, no. (%) 18 (15) 25 (49)
Table 1. Baseline Characteristics of the Patients (n = 170)
a Abbreviations: IFn; Interferon, RBV; Ribavirin
b In 3 cases, HCV RnA was assessed only qualitatively.971 Hematological Characteristics and SVR in Treatment of HCV Pawlowska M et al.
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Treated children, No.  Baseline After 12 Wk After 24 Wk End of Treatment
Group I; IFN + RBV (n = 119)
SVR a  62 13.7 ± 1.2 12.1 ± 1.1 b 12.1 ± 0.9 c 12.4 ± 1.2 c
Treatment-naïve 
Retherapy 
53
9
13.7 ± 1.3
13.3 ± 0.8
12.2 ± 1.1
11.5 ± 1.3
12.1 ± 0.9 c
11.6 ± 0.8
12.6± 1.2
11.6 ± 1.1
nR a  57 13.7 ± 1.1 12.1 ± 1.3 a 12.6±1.4 c 13.0±1.2 c
Treatment-naïve 
Retherapy
48
9
13.7 ± 0.9
13.8 ± 1.6
12.2 ± 1.2
11.9 ± 1.4
12.6 ± 1.1 c
12.2 ± 1.2
13.0 ± 1.1
12.4 ± 1.5
Group II; Treated With Peg-IFN-α-2b + RBV (n = 51)
SVR 24 13.5 ± 1.2 b 11.6 ± 1.1 b, c 11.7 ± 1.1 12.0 ± 1.5
Treatment-naïve 
Retherapy
15
9
13.7 ± 1.3
13.2 ± 1.3
11.5 ± 1.2
11.8 ± 0.9
11.8 ± 1.0
11.4 ± 1.1
12.0 ± 1.6
12.0 ± 1.4
nR  27 14.0 ± 1.0 b 12.4 ± 1.6 b, c 12.2 ± 1.5 12.6 ± 1.7
Treatment-naïve 
Retherapy 
10
17
13.7 ± 1.1
14.2 ± 0.9
12.0 ± 1.2
12.7 ± 1.8
12.6 ± 2.1
12.0 ± 1.1
12.1 ± 1.4
12.9 ± 1.8
Table 2. Serum Hemoglobin Levels (g/dL) in Treated Children
a Abbreviations: nR; non-responders, SVR; Sustained virological response
b Statistically significant differences, P < 0.05 (time dependent in one group)
c Statistically significant differences, P < 0.05 (between groups I and II) 
Such hematological complications were observed in our 
study as well. Such complications need to be monitored 
during the therapy (10-13). Hematologic toxicity is one of 
the most common reasons for dose reduction or discon-
tinuation of the treatment in patients with CHC infection. 
Dose reduction or treatment discontinuation may lower 
the SVR and result in 10–20% reduction in the patients’ 
adherence to the treatment regimen (14). The higher rate 
of cytopenia in adults, mainly in the elderly, can be ex-
plained by their lower level of baseline hemoglobin and 
neutrophil and platelet counts (15). Some authors have 
suggested that severe cytopenia is a marker for increased 
tumor-necrosis-factor (TnF) activity in patients, and this 
increased TnF activity translates into higher SVR (16). It 
is known that proinflammatory cytokines such as TnF-α 
and IFn-γ induce cell adhesion in endothelial cells and 
promote transmigration of leukocytes across endothe-
lial cells. ozaki et al. showed that combination therapy 
with TnF-α and IFn-γ causes disappearance of junctional 
adhesion molecules (JAMs) from intercellular junctions, 
and JAMs change their distribution in response to proin-
flammatory cytokines. This redistribution of JAM might 
be associated with the decrease in transendothelial mi-
gration of leukocytes at inflammatory sites (17). 
It is unclear if the decrease in the leukocyte count in 
patients treated with IFn-α is only a side effect or a char-
acteristic of IFn action and a marker of beneficial prog-
nosis. In a previous study, we analyzed the dynamics of 
leukocyte  count  associated  with  the  end-of-treatment 
response (eTR). All the examined children who achieved 
eTR, initially had shown early virological response - eVR, 
ALT normalization in the 12th week of therapy, and de-
crease in the leukocyte count. In the non-responders, the 
decrease in the leukocyte count was lower than that in 
the first group (a decrease of 23% and 37%, respectively). 
Decreased values of the leukocyte count did not warrant 
a modification in the treatment dose or schedule. our 
study proves that a mild decrease in the leukocyte count 
in the 12th week of therapy is associated with eVR and ALT-
activity normalization in the 12th week, during eTR, and 
in the follow-up period (18).
In a study by Suwantarat, at the end of the treatment, 
leukocyte and platelet counts were significantly lower 
in patients who had achieved SVR than in those who had 
not. Authors suggested that patients who developed leu-
copenia  or  thrombocytopenia  during  the  IFn  therapy 
Figure 1. Hemoglobin Levels observed in Children During Treatment. Group I (A) and group II (B)972 Hematological Characteristics and SVR in Treatment of HCV Pawlowska M et al.
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Figure 2. Leukocyte Count observed in Children During Treatment. Group I (A) and group II (B)
Figure 3. platelets Count observed in Children During Treatment. Group I (A) and Group II (B)
responded well to the therapy, and the side effects, if not 
severe, may not be indications for withholding or reduc-
ing the dose of IFn (16). In a study by Sievert et al, a high-
er SVR was achieved by patients who were infected with 
genotype 1 HCV and who developed anemia or decreased 
hemoglobin levels when treated with peg-IFn-α-2b + RBV 
(19). Similar observations were made in our study. The he-
moglobin levels and leukocyte and platelet counts dur-
ing the treatment, especially after 12 weeks of therapy, 
were lower in children who achieved SVR than in those 
Treated children, No. Baseline After 12 Wk After 24 Wk End of Treatment
IFN + RBV (n = 119)
SVR    62 6.78 ± 1.86 b 4.57 ± 1.83 b, c 4.50 ± 1.82 c 5.09 ± 1.86 c
Treatment-naïve 
Retherapy  
53
9
6.86 ± 1.93
6.32 ± 1.40
4.64 ± 1.92
4.21 ± 1.29
4.44 ± 1.71
4.85 ± 2.41
5.10 ± 1.93
5.01 ± 1.49
nR a 57 6.79 ± 3.16 b 4.36 ± 1.46 b, c 4.39 ± 1.63 5.29 ± 1.69 c
Treatment-naïve   
Retherapy  
48
9
6.89 ± 1.34
6.31 ± 2.11
4.44 ± 1.46
3.96 ± 1.42
4.35 ± 1.62
4.56 ± 1.71
5.29 ± 1.77
5.27±1.19
Peg-IFN-α-2b + RBV (n = 51)
SVR a 24 6.31 ± 1.53 b 3.32 ± 1.14 b, c 3.16 ± 0.85 c 4.22 ± 1.58 c
Treatment-naïve 
Retherapy  
15
9
6.60 ± 1.55
5.82 ± 1.15
3.52 ± 1.33
2.98 ± 0.65
2.95 ± 0.83
3.51 ± 0.82
3.85 ± 1.47
4.70 ± 1.68
nR   27 6.27 ± 1.37 b 3.54 ± 0.99 b, c 3.82 ± 1.13 4.35 ± 1.33 c
Treatment-naïve 
Retherapy 
10
17
6.44 ± 1.42
6.16 ± 1.36
3.56 ± 0.92
3.52 ± 1.06
3.93 ± 1.34
3.76 ± 1.02
4.66 ± 1.16
4.20 ± 1.41
Table 3. Leukocyte Count (103/µL) in Treated Children
a Abbreviations: nR; non-responders, SVR; Sustained virological response
b Statistically significant difference, P < 0.05 (time dependent in one group)
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Treated children, No. Baseline After 12 Wk After 24 Wk End of Treatment
IFN + RBV (n = 119)
SVR a   62 268 ± 66 b 221 ± 57 b 236 ± 66 261 ± 78
Treatment-naïve  
Retherapy 
53
9
267 ± 62
273 ± 86
220 ± 57
229 ± 61
235 ± 66
243 ± 66
255 ± 79
289 ± 71
nR a  57 269 ± 77 b 215±62 b 217 ± 61 b 258 ± 86
Treatment-naïve  
Retherapy  
48
9
272 ± 76
254 ± 80
217 ± 61
205 ± 66
221 ± 61
203 ± 64
261 ± 90
229 ± 50
Peg-IFN-α-2b + RBV (n = 51)
SVR  24 245 ± 65 b 172 ± 45 b 181 ± 55 215 ± 64
Treatment-naïve 
Retherapy 
15
9
244 ± 72
246 ± 55
166 ± 46
182 ± 45
171 ± 60
196 ± 44
190 ± 50
247 ± 69
nR  27 277 ± 70 b 198±45 b  204 ± 50 234 ± 45
Treatment-naïve  
Retherapy  
10
17
247 ± 48
295 ± 77
182 ± 47
208 ± 42
194 ± 49
209 ± 51
215 ± 37
244 ± 46
 
Table 4. Platelet Count (103/µL) in treated children
a Abbreviations: nR; non-responders, SVR; Sustained virological response
b Statistically significant difference, P < 0.05 (time dependent in one group)
who did not. In both the groups, a statistically significant 
decrease was observed in the mean serum hemoglobin 
levels in children who had attained SVR. A more statis-
tically significant decrease was observed in the serum 
hemoglobin levels after 12 weeks of therapy with peg-
IFn-α-2b + RBV in children who had achieved SVR than 
in the non-responders (P < 0.05). Analysis of leukocyte 
count according to the type of IFn administered showed 
that peg-IFn-α-2b had a more marked influence on the 
decrease in leukocyte count than recombinant IFn did. 
We observed a more statistically significant decrease in 
the leukocyte count after 12th and 24th weeks of treatment 
and at the end of therapy in children treated with peg-
IFn-α-2b + RBV than in those treated with recombinant 
IFn + RBV (SVR, P < 0.05). 
Similar  results  were  obtained  in  the  case  of  platelet 
count in children treated with peg-IFn-α-2b and RBV. In 
this group, we observed a decrease in the platelet count 
after 3 months of treatment, and this decrease was higher 
in the responders than in the non-responders. A stronger 
action of peg-IFn-α-2b associated with a more a marked 
decrease in the leukocyte and platelet count and a high-
er SVR induction was observed in the children treated 
with peg-IFn-α-2b  and RBV; this may be explained by the 
slightly higher treatment response in this group than 
that observed in the group treated with recombinant IFn 
despite the high ratio of children undergoing retherapy 
in children treated with peg-IFn-α-2b  and RBV.  The SVR of 
the naïve and retreated children was 53% and 50%, respec-
tively, in group I and 77% and 37%, respectively, in group II. 
Among 24 patients who achieved SVR during treatment 
with peg-IFn-α-2b and RBV, 15 were naïve responders and 
9 were previously treated patients. The highest decrease 
in the leukocyte and platelet counts were observed in 
treatment-naïve children treated with peg-IFnα-2b and 
RBV. However, it is important to note that 37% of the previ-
ously treated children in this group attained SVR. other 
factors that influenced SVR in this group of patients were 
the higher mean baseline HCV viral load and the lower 
ALT activity than that observed in children from group 
I. our data have shown that a mild decrease in hemoglo-
bin levels and leukocyte and platelet counts during treat-
ment with IFn and RBV in children with CHC infection 
may be factors associated with SVR induction. Thus, close 
monitoring of different hematological parameters dur-
ing treatment is necessary.
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